Eli Lilly and Company
LLY · NYSE
LLY · NYSE
Eli Lilly is a global pharmaceutical company that earns revenue by developing and selling branded medicines. Its portfolio includes diabetes and obesity treatments Mounjaro and Zepbound, as well as medicines such as Kisunla and Taltz; recent growth is concentrated in strong demand for Mounjaro and Zepbound. It sells medicines worldwide to patients through healthcare providers, pharmacies and other healthcare channels. The supplied evidence does not break out revenue by business segment or product. Lilly reported FY2025 revenue of $65.2 billion and net income of $20.6 billion, up from $45.0 billion and $10.6 billion, respectively, in FY2024.
The stock rose 5.13%, from the supplied starting reference of $1,306.69 to $1,373.70, with nearly all the advance arriving after Eli Lilly’s Thursday Q3 report. Shares fell to $1,273.46 on Oct. 23, then recovered only modestly through Wednesday, closing at $1,288.30. On Oct. 29 they jumped 6.6% from the prior close as quarterly revenue of $24.4 billion, up 39%, and earnings beat estimates, and Lilly raised its 2026 sales outlook to $91 billion–$92 billion. The higher sales outlook was tempered by a trimmed adjusted earnings outlook, while reports also highlighted pricing pressure: realized prices fell 15% as volume rose 53%.
Eli Lilly shares gained 4.88% over the supplied window, rising from $1,182.62 on October 12 to $1,240.34 on October 19. The stock first fell 1.36% on October 13, then climbed for three sessions, reaching $1,257.03 on October 16, before giving back $16.69 on October 19. The supplied evidence does not establish a company-specific catalyst for those moves during the week. It does show Lilly trading near record highs ahead of its Q3 earnings, while a MarketBeat report noted that technology stocks had taken a hit and pharma stocks were near new highs. Later headlines about Foundayo and analyst target changes cannot be confirmed as drivers of this window.
Eli Lilly rose $39.50, or 3.46%, to $1,182.62 over the week. Shares climbed from $1,143.12 on October 5 to $1,188.72 on October 7, then fell to $1,169.60 on October 8 before recovering most of the pullback by October 12. The main company-specific catalyst was European regulatory backing for Foundayo, Lilly’s oral weight-loss pill, which news coverage linked to the stock’s strongest weekly performance in nearly four months. Broader rotation from technology stocks into healthcare also supported the shares, according to Quartz and Stocks Down Under. The rebound followed Thursday’s pullback, but the supplied evidence does not identify a separate company-specific cause for that reversal.
LLY fell 2.29% over the reported period, from $1,184.63 to $1,157.49. The decline was concentrated early: the stock dropped to $1,142.85 by October 2, including a $27.55 fall on September 30 on the week’s highest listed volume, then stabilized on October 5 and rebounded 1.26% on October 6. That late recovery recouped part, but not all, of the earlier losses. The supplied evidence does not establish a company-specific catalyst for the net decline; a Quiver Quantitative headline noted the S&P 500 ETF was down 0.4% on a day of LLY price movement, but does not explain the broader market’s role across the period. Cantor Fitzgerald’s target increase is reported without a date, so it cannot be tied to the week’s trading.
Eli Lilly fell $32.04, or 2.71%, from $1,184.78 on September 28 to $1,149.85 on October 1. Shares were essentially flat through Tuesday, then dropped $27.55 on Wednesday—about 2.33%—on the week’s heaviest volume, and lost a further $7.23 Thursday. Company-specific coverage during the period highlighted positive Foundayo findings: Phase 3 ACHIEVE-4 results on cardiovascular safety, A1C and weight, and post-hoc ATTAIN-1 analyses of predicted diabetes and cardiovascular risk. Those reports do not establish a cause for the selloff, and the supplied evidence identifies no specific negative company announcement or broader market move that explains it. The stock therefore declined sharply late in the week despite favorable clinical news.
LLY gained 1.16%, from $1,137.82 to $1,150.99, over the reported period. Shares rose through September 22, closing at $1,170.14, before falling 1.64% on September 23 and giving back part of those gains. Coverage cited FDA approval of Eli Lilly’s once-weekly diabetes insulin as a reason for the stock to rise, although the supplied evidence does not establish when that news affected trading or quantify its contribution. The reported closes show the stock was already higher on September 17 and continued advancing on September 21–22; no other dated, company-specific catalyst or market benchmark is provided to explain those moves. Thus, the insulin approval is the clearest stated company driver, while the late-week pullback tempered the advance.
Eli Lilly shares fell 0.96% over the period, from $1,149.36 to $1,138.28. The stock initially declined to $1,123.91 on September 8, was essentially flat on September 9, slipped to $1,123.00 on September 10, and reached a period low of $1,115.70 on September 11 before rebounding 2.02% on September 14. The supplied evidence does not identify a dated company-specific announcement, earnings release, guidance change, or analyst action that explains the move. Articles discussed obesity-drug data, valuation, pricing, a $2.8 billion deal, and oncology progress, but no timing link to the trading sessions is provided. The week therefore appears to reflect price movement without an evidenced company-specific catalyst; broader market context was not supplied.
Eli Lilly fell 2.84% over the period, from $1,156.73 on August 31 to $1,123.91 on September 8. The stock initially edged higher, reaching $1,160.08 by September 2, before slipping on September 4 and then dropping 2.21% in the final session. Coverage linked the decline to concern around competitor Novartis’ cholesterol-drug setback and noted that Lilly fell more than the broader market, although the supplied evidence does not quantify the market move. Investors also continued weighing the company’s $3.8 billion AtaiBeckley acquisition and its efforts to build growth beyond GLP-1 drugs. No Lilly guidance change or earnings release is identified as a driver of the week.
LLY fell $16.50, or 1.40%, from $1,176.10 to $1,159.60 over the week. The main company-specific catalyst was Lilly’s Aug. 31 announcement that it intends to acquire Merida Biosciences for $2.875 billion, adding the Phase 1 MER511 autoimmune and allergic-disease program and supporting diversification beyond obesity and diabetes. The stock dropped $17.88 on Monday, then recovered only $3.35 across Tuesday and Wednesday before edging lower Thursday. Coverage also highlighted Lilly’s new FDA win for its weight-loss franchise and favorable Zepbound evidence, but those positives did not reverse the Monday decline. No broader market driver is identified in the supplied evidence.
Eli Lilly fell $68.30, or 5.49%, over the week, declining from $1,244.40 to $1,176.10. The stock slipped on Monday and Tuesday, then the decline accelerated Wednesday, when volume increased to 3.01 million shares, before extending lower Thursday on 2.74 million shares. Available coverage does not identify a company-specific event that explains the selloff or a material within-week reversal. The company’s news flow was broadly constructive, including FDA approval for Mounjaro to reduce cardiovascular risk in adults with type 2 diabetes, evidence linking Zepbound use with lower healthcare costs, and a reported deal involving Lilly and BHVN. The shares nevertheless weakened as the market reassessed valuation and the durability of GLP-1-driven growth.
LLY rose $35.40, or 2.93%, from $1,209.00 to $1,244.40 over the week. The advance was concentrated in Tuesday and Wednesday: after a nearly flat Monday close at $1,183.16, the stock gained 3.60% Tuesday and another 4.46% Wednesday on volume of 4.54 million shares. It then gave back $35.94, or 2.81%, Thursday, indicating profit-taking after the sharp midweek rally, before stabilizing Friday. The supplied evidence points to supportive company-specific sentiment around Lilly’s collaboration with Amplitude Therapeutics to develop taRNA vaccines and positive commentary that its GLP-1 portfolio outpaced Novo Nordisk’s in the second quarter. No explicit guidance change or analyst rating action explains Thursday’s reversal.
LLY rose 9.86%, or $110.58, from $1,121.36 on August 3 to $1,231.94 on August 10. The main catalyst was the August 5 earnings release, after which shares jumped 4.86% to $1,169.86 on heavier volume and gained another 1.89% Thursday. Coverage characterized the move as earnings-fueled and linked investor enthusiasm to GLP-1 momentum, including $98 million in second-quarter Foundayo sales and renewed expectations for oral obesity treatment. Shares gave back 0.52% Friday, but resumed the advance with a 3.90% gain on August 10, approaching a record high. Valuation and technical-breakout articles reinforced the positive tone, while insider-selling reports had limited apparent impact.
Eli Lilly fell 8.60%, from $1,220.66 to $1,115.68, declining in every reported session and reaching its lowest close on August 4 as volume rose to 4.10 million shares. The most identifiable company-specific development was the FDA’s Breakthrough Therapy designation for olomorasib in advanced pancreatic cancer, announced Monday, but it did not prevent a 2.4% decline that day. Investors were also positioning ahead of the August 5 earnings release, which was outside the reported trading window. Available evidence does not identify a negative company announcement during the week; the sustained retreat therefore appears driven mainly by pre-earnings positioning and broader reassessment of the stock’s valuation and growth expectations.
